News stories about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cipher Pharmaceuticals earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.4446637112034 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Cipher Pharmaceuticals (CPHR) opened at 2.99 on Friday. The stock has a 50 day moving average of $2.99 and a 200-day moving average of $2.99. Cipher Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $4.88.
WARNING: This report was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/11/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cipher-pharmaceuticals-nasdaqcphr-stock-price-updated-updated.html.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
